Capmatinib improves insulin sensitivity and inflammation in palmitate-treated C2C12 myocytes through the PPARδ/p38-dependent pathway
Sign Up to like & getrecommendations! Published in 2021 at "Molecular and Cellular Endocrinology"
DOI: 10.1016/j.mce.2021.111364
Abstract: Capmatinib (CAP) has been used to treat metastatic non-small lung cancer (NSCL) and suppress inflammation. It causes hypoglycemia in NSCL patients. Therefore, it is expected that CAP improves inflammation-mediated insulin resistance due to its anti-inflammatory… read more here.
Keywords: palmitate treated; palmitate; treated c2c12; inflammation ... See more keywords
Neuregulin-1β increases glucose uptake and promotes GLUT4 translocation in palmitate-treated C2C12 myotubes by activating PI3K/AKT signaling pathway
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.1066279
Abstract: Insulin resistance (IR) is a feature of type 2 diabetes (T2DM) accompanied by reduced glucose uptake and glucose transporter 4 (GLUT4) translocation by skeletal muscle. Neuregulin-1β (NRG-1β) is essential for myogenesis and the regulation of… read more here.
Keywords: translocation; akt signaling; c2c12 myotubes; glut4 translocation ... See more keywords